MOVING FORWARD


Premium Research actively contributed to the development of this article, published in 2023.
The article highlights the increasing global incidence of chronic kidney disease (CKD), with a significant proportion of patients progressing to end-stage renal disease (ESRD) and requiring renal replacement therapies (RRT). Peritoneal dialysis (PD) is one such RRT that offers advantages as a home-based treatment. In PD patients, the peritoneum is chronically exposed to PD fluids containing supra-physiological concentrations of glucose or other osmotic agents. This exposure leads to the activation of cellular and molecular damage processes, including inflammation and fibrosis. Notably, episodes of peritonitis further increase the inflammatory state and accelerate peritoneal injury.
This article reviews the role of immune cells in the damage to the peritoneal membrane (PM) caused by repeated exposure to PD fluids during treatment, as well as by bacterial or viral infections. It also discusses the anti-inflammatory properties of current clinical treatments for CKD patients on RRT and their potential effect on preserving PM integrity. Finally, given the global impact of the Coronavirus Disease 2019 (COVID-19) pandemic, the article also explores its implications for CKD and RRT.
Reference:
Int J Mol Sci. 2023 Mar 17;24(6):5763. doi: 10.3390/ijms24065763
https://www.mdpi.com/1422-0067/24/6/5763
